Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation.
Pagliuca S, Gurnari C, Hercus C, Hergalant S, Hong S, Dhuyser A, D'Aveni M, Aarnink A, Rubio MT, Feugier P, Ferraro F, Carraway HE, Sobecks R, Hamilton BK, Majhail NS, Visconte V, Maciejewski JP. Pagliuca S, et al. Among authors: feugier p. Nat Commun. 2023 May 31;14(1):3153. doi: 10.1038/s41467-023-38113-4. Nat Commun. 2023. PMID: 37258544 Free PMC article.
Systemic complement activation influences outcomes after allogeneic hematopoietic cell transplantation: A prospective French multicenter trial.
Notarantonio AB, D'aveni-Piney M, Pagliuca S, Ashraf Y, Galimard JE, Xhaard A, Marçais A, Suarez F, Brissot E, Feugier P, Urien S, Bouazza N, Jacquelin S, Meatchi T, Bruneval P, Frémeaux-Bacchi V, Peffault De Latour R, Hermine O, Durey-Dragon MA, Rubio MT. Notarantonio AB, et al. Among authors: feugier p. Am J Hematol. 2023 Oct;98(10):1559-1570. doi: 10.1002/ajh.27030. Epub 2023 Jul 22. Am J Hematol. 2023. PMID: 37483161 Free article.
ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome.
Parry EM, Lemvigh CK, Deng S, Dangle N, Ruthen N, Knisbacher BA, Broséus J, Hergalant S, Guièze R, Li S, Zhang W, Johnson C, Long JM, Yin S, Werner L, Anandappa A, Purroy N, Gohil S, Oliveira G, Bachireddy P, Shukla SA, Huang T, Khoury JD, Thakral B, Dickinson M, Tam C, Livak KJ, Getz G, Neuberg D, Feugier P, Kharchenko P, Wierda W, Olsen LR, Jain N, Wu CJ. Parry EM, et al. Among authors: feugier p. Cancer Cell. 2023 Oct 9;41(10):1803-1816.e8. doi: 10.1016/j.ccell.2023.08.013. Epub 2023 Sep 21. Cancer Cell. 2023. PMID: 37738974 Free PMC article.
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.
Tomowiak C, Poulain S, Nudel M, Feugier P, Herbaux C, Mahé B, Morel P, Aurran T, Tournilhac O, Leprêtre S, Assaad S, Villemagne B, Casasnovas O, Lhermitte A, Roos-Weil D, Torregrosa-Diaz J, Chevret S, Leblond V; on the behalf of the FILO group. Tomowiak C, et al. Among authors: feugier p. Ann Hematol. 2024 Nov 5. doi: 10.1007/s00277-024-06076-1. Online ahead of print. Ann Hematol. 2024. PMID: 39499299
Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.
Jiang L, Dreyling M, Hermine O, Mansmann U, Walewski J, Ribrag V, Thieblemont C, Pott C, Bachy E, Feugier P, Hübel K, Schumacher M, Hoster E. Jiang L, et al. Among authors: feugier p. Br J Haematol. 2025 Jan;206(1):159-166. doi: 10.1111/bjh.19854. Epub 2024 Oct 23. Br J Haematol. 2025. PMID: 39442921 Free PMC article. Clinical Trial.
[Nurturing and growing a community of department heads: Act 2 in haematology].
Houot R, Calmettes C, Park S, Pascal L, Peffault de Latour R, Pigneux A, Quinquenel A, Raffoux E, Thieblemont C, Touati M, Trebouet A, Vaida I, Wémeau M, Bastie JN, Bay JO, Cluzeau T, Cornillon J, Damaj G, Deconinck E, Feugier P, Fornecker LM, Gay J, Hermine O, Hospital MA, Hunault M, Jaccard A, Jardin F, Le Calloch R, Legros L, Leleu X, Lemonnier F, Malfuson JV, Morel P, Ochmann M, Orsini-Piocelle F, Gyan E. Houot R, et al. Among authors: feugier p. Bull Cancer. 2024 Oct;111(10):980-986. doi: 10.1016/j.bulcan.2024.06.014. Epub 2024 Sep 11. Bull Cancer. 2024. PMID: 39266427 Free article. French.
Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma-Final Analysis.
Maerevoet M, Casasnovas O, Cartron G, Morschhauser F, Thieblemont C, Bouabdallah K, Feugier P, Szablewski V, Becker S, Tilly H. Maerevoet M, et al. Among authors: feugier p. Cancers (Basel). 2024 Jul 26;16(15):2672. doi: 10.3390/cancers16152672. Cancers (Basel). 2024. PMID: 39123400 Free PMC article.
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial.
Guièze R, Ysebaert L, Roos-Weil D, Fornecker LM, Ferrant E, Molina L, Aurran T, Clavert A, de Guibert S, Michallet AS, Saad A, Drénou B, Quittet P, Hivert B, Laribi K, Gay J, Quinquenel A, Broseus J, Rouille V, Schwartz D, Magnin B, Lazarian G, Véronèse L, de Antonio M, Laurent C, Tournilhac O, Pereira B, Feugier P. Guièze R, et al. Among authors: feugier p. Nat Commun. 2024 Aug 9;15(1):6822. doi: 10.1038/s41467-024-51264-2. Nat Commun. 2024. PMID: 39122717 Free PMC article. Clinical Trial.
301 results